72
Clarivate completes $600M sale of Life Sciences unit to Altaris
Why it matters
Clarivate closed the sale of its Life Sciences and Healthcare business to Altaris for $500M in cash plus a $75M senior note and $25M in deferred consideration, totaling $600M. This is a material asset disposition that reduces CLVT's business footprint but generates significant liquidity for debt reduction or strategic reinvestment.
In plain language
Clarivate sold off one of its major divisions to Altaris for $600 million, receiving most of the cash upfront. This shrinks the company but puts cash on the balance sheet.
Exposure
CLVT ▲
Price check
not measured: no fresh price at the time of scoringHow this is measured
Information only. AURA does not give buy or sell recommendations.